TP0438836

sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor

Also Known As:

1-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-3-(4-(4-hydroxy-2-methyl-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenethyl)urea

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - TP0438836: 1
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzyl Compounds: 2
        TP0438836: 1
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - TP0438836: 1

Experts

1.	Amada, Hideaki: 1 article (12/2018)
2.	Io, Fusayo: 1 article (12/2018)
3.	Kakinuma, Hiroyuki: 1 article (12/2018)
4.	Kobashi, Yohei: 1 article (12/2018)
5.	Kuroda, Shoichi: 1 article (12/2018)
6.	Oi, Takahiro: 1 article (12/2018)
7.	Okumura-Kitajima, Lisa: 1 article (12/2018)
8.	Yamamto, Koji: 1 article (12/2018)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 12/01/2018 - "Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes."

Related Drugs and Biologics

1.	Sodium
2.	Glucose (Dextrose)